Sanofi: Frexalimab Phase 2 Trial Meets Primary Goal In Relapsing Multiple Sclerosis

(RTTNews) - French drug major Sanofi S.A. (SNYNF, SNY) announced Wednesday positive Phase 2 data of novel investigational anti-CD40L antibody frex...

Related Keywords

France ,French ,Gavin Giovannoni ,Queen Mary University Of London ,Blizard Institute ,Consortium Of Multiple Sclerosis Centers ,More Such Health News ,London School Of Medicine ,Multiple Sclerosis Centers ,London School ,Queen Mary University ,